Stratified cost-effectiveness analysis: a framework for establishing efficient limited use criteria.

Area of Science:

• Health economics
• Health services research
• Clinical trial analysis

Background:

• Cost-effectiveness of new health technologies varies based on patient subgroups and treatment circumstances.
• Healthcare payers often restrict reimbursement to narrower patient groups than product licensing suggests, using clinical or demographic criteria.
• Limited guidance exists for estimating and interpreting stratified cost-effectiveness analyses.

Purpose of the Study:

• To present a framework for estimating the benefits of stratifying patients in cost-effectiveness analyses.
• To incorporate the opportunity cost of non-adherence to stratification criteria.
• To account for efficiency losses due to equity considerations in reimbursement decisions.

Main Methods:

• Development of a novel framework for stratified cost-effectiveness analysis.
• Inclusion of adherence to stratification criteria as a factor.
• Quantification of efficiency losses related to equity concerns.

Main Results:

• The framework allows for a more nuanced estimation of cost-effectiveness benefits.
• It quantifies the impact of patient adherence on overall value.
• The approach addresses the trade-offs between efficiency and equity.

Conclusions:

• Stratified cost-effectiveness analysis requires careful consideration of patient selection and adherence.
• The proposed framework provides a method to estimate benefits while accounting for practical implementation challenges.
• This approach can aid payers in making more informed reimbursement decisions for new health technologies.